Anticoagulants: Old and new

Hamostaseologie

Volumn 31, Issue 4, 2011, Pages 229-235

  Levi, M ^a   Eerenberg, E S ^a   Kampuisen, P W ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Anticoagulants; Dabigatran; Heparin; Pentasaccharide; Rivaroxaban; Vitamin K antagonists

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIHISTAMINIC AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DABIGATRAN; ENOXAPARIN; FONDAPARINUX; HEPARIN; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; NONSTEROID ANTIINFLAMMATORY AGENT; OXIDOREDUCTASE; PHENPROCOUMON; PROTAMINE SULFATE; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; STEROID; THROMBIN; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1 PROTEIN; VITAMIN K GROUP; WARFARIN; XIMELAGATRAN;

AGE; ANTICOAGULANT THERAPY; ARTERIAL THROMBOEMBOLISM; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM BLEEDING; CENTRAL NERVOUS SYSTEM DISEASE; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DNA POLYMORPHISM; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG USE; GASTROINTESTINAL HEMORRHAGE; HUMAN; INTERNATIONAL NORMALIZED RATIO; META ANALYSIS (TOPIC); PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; THROMBIN TIME; THROMBOCYTE FUNCTION; THROMBOEMBOLISM; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; COMORBIDITY; DRUG TOXICITY; HEMORRHAGE; HUMANS; PREVALENCE; RISK ASSESSMENT; RISK MANAGEMENT; THROMBOEMBOLISM; VITAMIN K;

EID: 83755206985     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/ha-1153     Document Type: Review

References (80)

1. Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007; 356. 2301-2311.
2. th ed). Chest 2008; 133 (6 Suppl): 257S-298S.
3. Eikelboom JW, Mehta SR, Anand SS, Xie C et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114: 774-782.
4. Algra A. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT). a randomised controlled trial. Lancet Neurol 2007; 6: 115-124.
5. Levi MM, Eerenberg E, Lowenberg E, Kamphuisen PW. Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management. Neth J Med 2010; 68: 68-76.
6. Saour JN, Sieck JO, Mamo LA, Gallus AS. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med 1990; 322: 428-432.
7. Schmeits PC, Pequeriaux NC, van Geest-Daalderop JH et al. Investigating unexpected INRs. in search of the culprit -adherence, interactions, genetics, and superwarfarin. Neth J Med 2009; 67: 76-78.
8. Vink R, Kraaijenhagen RA, Hutten BA et al. The optimal intensity of vitamin K antagonists in patients with mechanical heart valves. a meta-analysis. J Am Coll Cardiol 2003; 42: 2042-2048.
9. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120: 897-902.
10. Cannegieter SC, Rosendaal FR, Wintzen AR et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11-17.
11. Palareti G, Leali N, Coccheri S et al. Bleeding complications of oral anticoagulant treatment. an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-428.
12. th ed). Chest 2008; 133 (6 Suppl): 160S-198S.
13. Fitzmaurice DA, Murray ET, Gee KM et al. A randomised controlled trial of patient self management of oral anticoagulation treatment compared with primary care management. J Clin Pathol 2002; 55: 845-849.
14. Poller L, Shiach CR, MacCallum PK et al. Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation. Lancet 1998; 352: 1505-1509.
15. Ageno W, Johnson J, Nowacki B, Turpie AG. A computer generated induction system for hospitalized patients starting on oral anticoagulant therapy. Thromb Haemost 2000; 83: 849-852.
16. Levi M, de Peuter O, Kamphuisen PW. Management strategies for optimal control of anticoagulation in patients with atrial fibrillation. Semin Thromb Hemost 2009; 35: 560-567.
17. Hutten BA, Lensing AW, Kraaijenhagen RA, Prins MH. Safety of treatment with oral anticoagulants in the elderly. A systematic review. Drugs Aging 1999; 14: 303-312.
18. Fang MC, Chang Y, Hylek EM et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004; 141: 745-752.
19. Higashi MK, Veenstra DL, Kondo LM et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287: 1690-1698.
20. Reitsma PH, van der Heijden JF, Groot AP et al. A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med 2005; 2: e312.
21. Levi M, Hovingh GK, Cannegieter SC et al. Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood 2008; 111: 4471-4476.
22. Hart RG, Benavente O, Pearce LA. Increased risk of intracranial hemorrhage when aspirin is combined with warfarin. A meta-analysis and hypothesis. Cerebro vasc Dis 1999; 9: 215-217.
23. Rothberg MB, Celestin C, Fiore LD et al. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome. meta-analysis with estimates of risk and benefit. Ann Intern Med 2005; 143: 241-250.
24. Hallas J, Dall M, Andries A et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding. population based case-control study. Br Med J 2006; 333: 726.
25. Mellemkjaer L, Blot WJ, Sorensen HT et al. Upper gastrointestinal bleeding among users of NSAIDs. a population-based cohort study in Denmark. Br J Clin Pharmacol 2002; 53: 173-181.
26. Battistella M, Mamdami MM, Juurlink DN et al. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med 2005; 165: 189-192.
27. Rothwell PM. External validity of randomised controlled trials. "to whom do the results of this trial apply?". Lancet 2005; 365: 82-93.
28. Levi M, Hovingh K. Bleeding complications in patients on anticoagulants who would have been disqualified for clinical trials. Thromb Haemost 2008; 100: 1047-1051.
29. Abdelhafiz AH, Wheeldon NM. Results of an openlabel, prospective study of anticoagulant therapy for atrial fibrillation in an outpatient anticoagulation clinic. Clin Ther 2004; 26: 1470-1478.
30. Jackson SL, Peterson GM, Vial JH et al. Outcomes in the management of atrial fibrillation. clinical trial results can apply in practice. Intern Med J 2001; 31: 329-336.
31. Levi M. Emergency reversal of antithrombotic treatment. Intern Emerg Med 2008; 7: 21-28
32. Dentali F, Ageno W, Crowther M. Treatment of coumarin-associated coagulopathy. a systematic review and proposed treatment algorithms. J Thromb Haemost 2006; 4: 1853-1863.
33. Crowther MA, Ageno W, Garcia D et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin. Ann Intern Med 2009; 150: 293-300.
34. Crowther MA, Douketis JD, Schnurr T et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med 2002; 20; 137: 251-254.
35. Lubetsky A, Yonath H, Olchovsky D et al. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation. a prospective randomized controlled study. Arch Intern Med 2003; 163: 2469-2473.
36. Van Geest-Daalderop JH, Hutten BA, Pequeriaux NC et al. Invasive procedures in the outpatient setting. Managing the short-acting acenocoumarol and the long-acting phenprocoumon. Thromb Haemost 2007; 98: 747-755.
37. Dentali F, Ageno W. Management of coumarin-associated coagulopathy in the non-bleeding patient: a systematic review. Haematologica 2004; 89: 857-862.
38. Aguilar MI, Hart RG, Kase CS et al. Treatment of warfarin-associated intracerebral hemorrhage. Literature review and expert opinion. Mayo Clin Proc 2007; 82: 82-92.
39. Van AL, Eijkhout HW, Kamphuis JS et al. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy. an open, prospective randomized controlled trial. Thromb Res 2006; 118: 313-320.
40. Kessler CM. Urgent reversal of warfarin with prothrombin complex concentrate. where are the evidence-based data? J Thromb Haemost 2006; 4: 963-966.
41. Pabinger I, Brenner B, Kalina U et al. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal. a prospective multinational clinical trial. J Thromb Haemost 2008; 6: 622-631.
42. Levi M. Disseminated intravascular coagulation. Crit Care Med 2007; 35: 2191-2195.
43. Dager WE, King JH, Regalia RC et al. Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin. Pharmacotherapy 2006; 26: 1091-1098.
44. Sorensen B, Johansen P, Nielsen GL et al. Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis. clinical and biochemical aspects. Blood Coagul Fibrinolysis 2003; 14: 469-477.
45. Fernandez-Fernandez FJ, del Castillo-Fraile M. Acute abdominal pain in a patient receiving enoxaparin. Neth J Med 2009; 67: 243-244.
46. th ed). Chest 2008; 133 (6 Suppl): 141S-159S.
47. Lindblad B, Borgstrom A, Wakefield TW et al. Protamine reversal of anticoagulation achieved with a low molecular weight heparin. The effects on eicosanoids, clotting and complement factors. Thromb Res 1987; 48: 31-40.
48. Massonnet-Castel S, Pelissier E, Bara L et al. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate. in vitro and in vivo study during cardiac surgery with extracorporeal circulation. Haemostasis 1986; 16: 139-146.
49. Van Ryn-McKenna J, Cai L, Ofosu FA et al. Neutralization of enoxaparine-induced bleeding by protamine sulfate. Thromb Haemost 1990; 63: 271-274.
50. Bang CJ, Berstad A, Talstad I. Incomplete reversal of enoxaparin-induced bleeding by protamine sulfate. Haemostasis 1991; 21: 155-160.
51. Caplan SN, Berkman EM. Protamine sulfate and fish allergy. N Engl J Med 1976; 295: 172.
52. Fearn SJ, Parry AD, Picton AJ et al. Should heparin be reversed after carotid endarterectomy? A randomised prospective trial. Eur J Vasc Endovasc Surg 1997; 13: 394-397.
53. Mauney MC, Buchanan SA, Lawrence WA et al. Stroke rate is markedly reduced after carotid endarterectomy by avoidance of protamine. J Vasc Surg 1995; 22: 264-269.
54. Dellagrammaticas D, Lewis SC, Gough MJ. Is heparin reversal with protamine after carotid endarterectomy dangerous? Eur J Vasc Endovasc Surg 2008; 36: 41-44.
55. D'Ambra M. Restoration of the normal coagulation process. advances in therapies to antagonize heparin. J Cardiovasc Pharmacol 1996; 27 Suppl 1: S58-62.
56. Despotis GJ, Summerfield AL, Joist JH et al. In vitro reversal of heparin effect with heparinase. evaluation with whole blood prothrombin time and activated partial thromboplastin time in cardiac surgical patients. Anesth Analg 1994; 79: 670-674.
57. Tao W, Deyo DJ, Brunston RL Jr et al. Extracorporeal heparin adsorption following cardiopulmonary bypass with a heparin removal device--an alternative to protamine. Crit Care Med 1998; 26: 1096-1102.
58. Buller HR. Treatment of symptomatic venous thromboembolism. improving outcomes. Semin Thromb Hemost 2002; 28 Suppl 2: 41-48.
59. Crowther MA, Warkentin TE. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy. focus on new anticoagulant agents. Blood 2008; 111: 4871-4879.
60. Bijsterveld NR, Vink R, van Aken BE et al. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br J Haematol 2004; 124: 653-658.
61. Bijsterveld NR, Moons AH, Boekholdt SM et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002; 106: 2550-2554.
62. Levi M. New antithrombotics in the treatment of thromboembolic disease. Eur J Intern Med 2005; 16: 230-237.
63. Strebel N, Prins M, Agnelli G, Buller HR. Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecularweight heparin in elective hip surgery? Arch Intern Med 2002; 162: 1451-1456.
64. Agnelli G, Gallus A, Goldhaber SZ et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939). the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation 2007; 116: 180-187.
65. Shantsila E, Lip GY. Apixaban, an oral, direct inhibitor of activated Factor Xa. Curr Opin Investig Drugs 2008; 9: 1020-1033.
66. Turpie AG, Lassen MR, Davidson BL et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4). a randomised trial. Lancet 2009; 373: 1673-1680.
67. Lassen MR, Ageno W, Borris LC et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-2786.
68. Lassen MR, Raskob GE, Gallus A et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009; 361: 594-604.
69. Buller H, Deitchman D, Prins M, Segers A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008; 6: 1313-1318.
70. Buller HR, Lensing AW, Prins MH et al. A doseranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. the Einstein-DVT Dose-Ranging Study. Blood 2008; 112: 2242-2247.
71. Bauersachs R, Berkowitz SD, Brenner B et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
72. Mega JL, Braunwald E, Mohanavelu S et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46). a randomised, double-blind, phase II trial. Lancet 2009; 374: 29-38.
73. Alexander JH, Becker RC, Bhatt DL et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome. results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009; 119: 2877-2885.
74. Weitz JI, Buller HR. Direct thrombin inhibitors in acute coronary syndromes. present and future. Circulation 2002; 105: 1004-1011.
75. Wahlander K, Lapidus L, Olsson CG et al. Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. Thromb Res 2002; 107: 93-99.
76. Eriksson BI, Smith H, Yasothan U, Kirkpatrick P. Dabigatran etexilate. Nat Rev Drug Discov 2008; 7: 557-558.
77. Eriksson BI, Dahl OE, Rosencher N et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement. a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-956.
78. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
79. Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352.
80. Woltz M, Levi M, Sarich TC et al. Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers. Thromb Haemost 2004; 91: 1090-1096.